TLSA

0.62527.46%
JP

John Patrick Brancaccio

Independent Non-Executive Director

Mr. John Patrick Brancaccio, C.P.A, serves as Independent Non-Executive Director at Tiziana Life Sciences plc since July 2020. He is an Independent Non-Executive Director at OKYO Pharma Limited since June 10, 2020. He served as Executive Chairman at Hepion Pharmaceuticals, Inc. since March 15, 2024 until June 30, 2025 and served as its Interim CFO since August 06, 2024 until June 30, 2025 and served as its Interim CEO since August 06, 2024 until June 16, 2025. He had been an Independent Director of Hepion Pharmaceuticals, Inc. (formerly known as ContraVir Pharmaceuticals, Inc.) since May 15, 2013 until March 2024 and served as its Independent Chairman of the Board since February 20, 2024 until March 2024. He is Independent Director of Accustem Sciences, Inc. since March 2021. Mr. Brancaccio was the Chief Financial Officer of Accelerated Technologies, Inc. from April 2004 to May 2017. Mr. Brancaccio serves as the Chief Financial Officer at Orchestra Medical Ventures, LLC. He has been a Financial Consultant to life sciences companies. Mr. Brancaccio served specific companies, which are at development stage and focusing on the discovery and development of pharmaceutical and biopharmaceutical compounds and technology platforms. He served as the Chief Financial Officer of Memory Pharmaceuticals Corporation from May 2002 to March 2004 and served as its Secretary and Treasurer. He served as an Acting Chief Financial Officer and Treasurer of Memory Pharmaceuticals, Inc. He is a financial executive with extensive international and domestic experience in pharmaceutical and biotechnology for privately and publicly held companies. Prior to Memory Pharmaceuticals, Mr. Brancaccio served as Chief Financial Officer and Chief Operating Officer of Eline Entertainment Group, Inc. from 2000 to 2002, where he oversaw the roll up of several related companies into the group and completed private equity financing placements. He served as the President at Eline Entertainment Group, Inc. since January 1, 2001. He was associated with Zambon Corporation and served as its Senior Vice President of Finance and Chief Financial Officer and having responsibility for operations in North, Central and South America. He served as the Chief Financial Officer of Deven Associates, Inc. Prior to Eline Group; he held several executive positions in public and private companies including Atlantic Pharmaceuticals, Deven International and Health Learning Systems. Mr. Brancaccio served as the Chief Financial Officer and Americas Area Controller for Zambon Group. He serves as Independent Director of Actavia Life Sciences, Inc. (formerly known as Rasna Therapeutics, Inc.) since September 2016. He served as a Director at Callisto Pharmaceuticals Inc. from April 2004 to January 2013 and has served at Tamir Biotechnology, Inc. (formerly Alfacell Corporation) since April 2004 until May 2020. He had been an Independent Director of Cardiff Oncology, Inc. (formerly known as TrovaGene, Inc.) since December 1, 2005 until June 09, 2022. He had been an Independent Director of Synergy Pharmaceuticals, Inc. since July 2008 until April 2019. He served as Director of Fermavir Pharmaceuticals, Inc. since September 24, 2005. He served as a Director of Used Kar Parts Inc. since December 1, 2005. He served as a Director of Eline Entertainment Group, Inc. since January 2001 and Venus Beauty Supply Inc. since September 24, 2005. He affiliated with The American Institute of Certified Public Accountants and The Financial Executives Institute. He is a retired CPA. Mr. Brancaccio was a Certified Public Accountant in the State of New Jersey (AICPA). He is a Graduate of Seton Hall University. He is Director at AccuStem Sciences Limited.

公司职务